Sharklet Technologies

About:

Sharklet Technologies, Inc. is a biotechnology company that develops and brings to market surface technologies.

Website: http://www.sharklet.com/

Top Investors: National Institute of Diabetes and Digestive and Kidney Diseases

Description:

Sharklet Technologies, Inc. is a biotechnology company that develops and brings to market surface technologies that manage microorganisms to make the world a healthier, environmentally safer and better place. The company’s patented, core technology, called Sharklet™, is the first no-kill, non-toxic and environmentally-friendly surface texture designed to inhibit bacterial growth including MRSA, E. coli, Staph a., Pseudomonas aeruginosa, VRE and a host of other bacteria. The Sharklet surface is comprised of millions of microscopic diamonds that are arranged into a distinct texture. It is this texture that bacteria find inhospitable for growth. Inspired by the natural microbe-resistant properties of sharkskin, Sharklet is a simple solution for a complex problem. Sharklet is a platform technology with broad applications from germ-prone surfaces in healthcare and childcare facilities to consumer goods and medical devices. The company has already licensed its technology for a urinary catheter that is currently in clinical trials with the aim to reduce catheter-associated urinary tract infections.

Total Funding Amount:

$3.67M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Aurora, Colorado, United States

Founded Date:

2008-02-01

Contact Email:

Info(AT)sharklet.com

Founders:

Anthony Brennan, Jason Morton, Mark Spiecker

Number of Employees:

11-50

Last Funding Date:

2014-12-26

IPO Status:

Private

Industries:

© 2025 bioDAO.ai